$20.30 +0.05 (0.25%) Acorda Therapeutics Inc - NASDAQ

Dec. 2, 2016 | 04:00 PM

Quotes

  1. Quotes

  2. Charts

  3. Analysis

  4. Options

  5. Historical



Last Trade: 20.30
Trade Time: Dec 02 04:00 PM Eastern Daylight Time
Change: +0.05 (0.25%)
Prev Close: 20.25
Open: 20.20
Bid: 20.25
Ask: 20.30
  1. No results found.
  1. Seth Klarman Buys 763,889 Shares in Drug Development Company

    GuruFocus | Feb. 15, 2016 | 14:39PM EST
  2. Acorda Therapeutics Confirms It Entered Into A Patent Litigation Settlement Deal With Par Pharma

    Benzinga | Jan. 21, 2016 | 09:29AM EST
  3. Benzinga's M&A Chatter for Tuesday January 19, 2015

    Benzinga | Jan. 19, 2016 | 21:26PM EST
  4. Mid-Afternoon Market Update: US Stocks Turn Red; Crude Oil Falls Over 3%

    Benzinga | Jan. 19, 2016 | 14:48PM EST
  5. Mid-Day Market Update: Dow Surges 150 Points; Progressive Waste Shares Spike Higher

    Benzinga | Jan. 19, 2016 | 12:21PM EST
  6. Mid-Morning Market Update: Markets Open Higher; Bank of America Earnings Top Views

    Benzinga | Jan. 19, 2016 | 10:05AM EST
  7. Acorda Therapeutics To Acquire Biotie Therapies To Boost Its Parkinson's Disease Therapeutic Development

    Benzinga | Jan. 19, 2016 | 09:40AM EST
  8. Acorda to Acquire Biotie Therapies for $25.60/ADS

    Benzinga | Jan. 19, 2016 | 04:15AM EST
  9. Kyle Bass Explains The 'Patent Trolls' Situation In The Pharma Industry

    Benzinga | Jan. 2, 2016 | 20:38PM EST
  10. Acorda to Present New rHIgM22 and AMPYRA Data at 31st Congress of European Committee for Treatment and Research in MS

    Benzinga | Oct. 7, 2015 | 06:05AM EST
  11. Acorda-Allergan surprise deal

    IBD | Oct. 5, 2015 | 17:46PM EST
  12. Acorda, Allergan Make Surprise Deal On Ampyra Patent

    IBD | Oct. 5, 2015 | 14:03PM EST
  13. Benzinga's Volume Movers

    Benzinga | Oct. 5, 2015 | 09:39AM EST
  14. Acorda Therapeutics 8-K Says Co. Agrees With Actavis to Resolve Pending Patent Litigation

    Benzinga | Oct. 5, 2015 | 06:07AM EST
  15. Acorda Therapeutics 8-K Filing Shows Company WIll Oppose Requests To Institute For IPRS, Will Oppose Full Proceedings And Defend Patents

    Benzinga | Sep. 3, 2015 | 15:29PM EST
Trading Center